Predictors of clinical response to biologics in psoriasis: A systematic review and meta-analysis.
J Eur Acad Dermatol VenereolApr 17, 2026 (epub)
Xuerui Mao, Shuo Meng, Panyu Wu et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined predictors of biologic efficacy in psoriasis, analyzing data from 30 studies involving 13,902 patients. Key findings indicate that older age, higher body mass index, comorbidities, and involvement of special areas negatively impact treatment response, while a positive family history is associated with improved outcomes.
Key findings
- Older age is a negative predictor of clearance (OR 0.99, 95% CI 0.98-0.99, p < 0.001).
- Higher body mass index negatively affects treatment response (OR 0.94, 95% CI 0.92-0.97, p < 0.001).
- Comorbidities are linked to poorer biologic response (OR 0.75, 95% CI 0.63-0.9, p = 0.002).
- A positive family history is associated with better treatment outcomes (OR 1.42, 95% CI 1.18-1.71, p < 0.001).
Why it matters
Understanding predictors of response to biologics in psoriasis can enhance treatment personalization, allowing clinicians to better stratify patients based on their likelihood of achieving skin clearance and optimize therapeutic strategies.